Mumbai Univ alumnus appointed to cell therapy firm's scientific board in NJ

Dr. Shishir Gadam joins the company with close to three decades of industry experience.

Dr. Shishir Gadam / LinkedIn/@Shishir Gadam

Made Scientific, a New Jersey based contract development and manufacturing organization (CDMO) specializing in cell therapies, has announced that Shishir Gadam, Ph.D, will be part of their newly formed Scientific Advisory Board (SAB).

Dr. Gadam is the Chief Technical Officer at Marea Therapeutics and former Head of Technical Operations at Cargo Therapeutics, where he built manufacturing infrastructure and advanced novel CAR-T programs.

He has also served as the Global Head of Cell Therapy MS&T at Juno Therapeutics, (now acquired by Bristol Myers Squibb), playing a key role in launching two commercial CAR-T therapies.

ALSO READ: VitalEdge CEO Vikram Savkar joins equipment distributor foundation's board

He holds a Ph.D. in Biochemical Engineering from Rensselaer Polytechnic Institute. Before moving to New York for his doctorate, Gadam obtained a Bachelor's degree in Chemical Engineering from the University of Mumbai and a Master's degree in Chemical Engineering from West Virginia University.

Along with Gadam, Miguel Forte, Paul K. Wotton, and Young K. Hong were also appointed to the organization's Scientific Board.

In a press statement, Made Scientific highlighted the value that the Board brings to the table and said, "Their insights will help drive strategic initiatives at Made focused on lowering the cost of goods (COGS) for cell therapies and enabling partners to deliver more accessible, reliable, and transformative therapies to patients globally."

Syed T. Husain, Chairman and CEO of Made Scientific, said, "The establishment of our Scientific Advisory Board marks a pivotal moment in our commitment to innovation."

He further added, "Miguel, Paul, Shishir, and Young each bring world-class expertise across cell therapy, manufacturing science, commercialization, and clinical practice. Their guidance will directly shape our service priorities, ensuring we deliver advanced, accessible, and scalable solutions for patients globally."

Made Scientific plans to further expand the SAB later this year.

Comments

This is a Premium Article, available exclusively to our subscribers.

Read 500+ such News or articles every month by subscribing today!
Monthly

Free

Limited Access

Limited View

Free weekly E-Paper

Subscribe Now
Monthly

$10

Full Access

Unlimited View

Free weekly E-Paper

Free daily newsletter

Subscribe Now
Annual

$50

Full Access

Unlimited View

Free weekly E-Paper

Free daily newsletter

Subscribe Now
Start the conversation

Become a member of New India Abroad to start commenting.

Sign Up Now

Already have an account? Login